General Announcement::Glenmarks Ryaltris nasal spray approved in Europe for treatment of allergic rhinitis

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Apr-2021 16:40:14
Status
New
Announcement Sub Title
Glenmarks Ryaltris nasal spray approved in Europe for treatment of allergic rhinitis
Announcement Reference
SG210426OTHRPQVJ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary and Compliance Officer
Effective Date and Time of the event
26/04/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmarks Ryaltris nasal spray now approved in Europe for the first line treatment
of allergic rhinitis in patients over 12 years of age

Attachments

SGX PR 26042021_Signed.pdf
Total size =1086K